Haematologica ©2013 Ferrata Storti Foundation. This is an open-access paper.
... In conclusion, single-agent plitidepsin has shown antitumor activity and a tolerable safety profile in patients with relapsed/refractory non-cutaneous PTCL.
These result therefore support the conduct of further clinical trials to evaluate plitidepsin-containing combined therapies in this disease setting .
...